Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects

Trial Profile

Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Jun 2017 Results (n=26) presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by
    • 05 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top